Leader in optical molecular imaging products selects clinivation team to lead clinical development of award-winning breast cancer imaging system.
Framingham, MA, January 12, 2004 – clinivation, Inc. announced today that ART, Advanced Research Technologies, Inc. (TSX: ARA) has selected clinivation to provide turnkey, outsourced clinical development solutions and services for its SoftScan® optical breast imaging system.
“ART is a leader in optical molecular imaging and is dedicated to the development of state-of-the-art technology applications for the life sciences sector, and we are honored to have been selected to lead the clinical development of their SoftScan optical breast imaging system,” said Joseph Kozikowski, M.D., clinivation’s Founder, Chairman, and Chief Executive Officer of clinivation.
Clinical development will be conducted at leading research centers in the world’s leading markets.
About ART, Advanced Research Technologies, Inc.
ART Advanced Research Technologies, Inc. is a leader in optical molecular imaging products for the healthcare and pharmaceutical industries. ART has developed two products based on its innovative technology. The first is eXplore Optix™, a molecular imaging device designed for monitoring physiological changes in living systems at the pre-clinical study phases of new drugs. eXplore Optix™ is distributed by GE Healthcare and is used by industry and academic leaders worldwide to bring new and better treatments to patients faster. The second is SoftScan®, a medical imaging device designed to improve the diagnosis and treatment of breast cancer.
For more information about ART, visit the Company’s Web site at www.art.ca
